Past daily editions — longevity, genomics, and disease-modifying AI — with dates and source links. The homepage always shows the latest set.
Nature “Bigger than CRISPR” genome-editors feature; Life Biosciences ER-100 OSK Phase 1; MINT Bxb1 serine integrase; enIS621 bridge recombinase; plus the research-is-not-a-cure caveat card.
CTX310 ANGPTL3 one-year durability (NEJM, ScienceDaily, Cleveland Clinic); eCgCas12n mini Cas12n (Molecular Systems Biology, Scienmag); CRISPR_SCD001 sickle-cell product (Molecular Therapy, UCLA); DNG64-CAR-V spinal-fluid authorization (Aveni, EIN); Genflow GF-1002/SIRT6 SLAB dog trial (Investegate RNS); plus the research-is-not-a-cure caveat.
Silencing ALDH3B2 converts human pancreatic duct cells into beta-like cells in a preclinical transplant model (Science Translational Medicine); REGENXBIO sura-vec three-year durability in NPDR (Phase II ALTITUDE); YolTech YOLT-202 first-in-human adenine base editing proof of concept in PiZZ AATD (n=4); two child deaths in Chinese gene-editing trials and where the field goes next (Nature); Longeveron laromestrocel reaches the XPRIZE Healthspan finals for aging frailty.
FDA clears Prime Medicine’s IND for PM647, an in vivo Prime Editor for alpha-1 antitrypsin deficiency (Phase 1/2); targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence in mice (Signal Transduction and Targeted Therapy); Neisseria flavescens as a geroprotective oral commensal (Nature Aging); senescence DNA methylation signatures not reversed by senolytics (Aging Cell); genome-wide in vivo CRISPRi maps age-dependent neuronal vulnerability (Neuron).
UAB doses world’s first patient in investigational BAG3 gene therapy for dilated cardiomyopathy (Alexion, AstraZeneca Rare Disease; Phase 1/2); NEJM long-term etu-cel (Waskyra) results in Wiskott-Aldrich syndrome (n=27, ≥5.7 years); Ocugen OCU400 Bahamas LARTA provisional approval / expanded access for retinitis pigmentosa; Rocket RP-A501 FDA alignment on pivotal Phase 2 in Danon disease; caloric restriction and a composite aging-biomarker index (GeroScience, pooled RCTs).
GRAIL Galleri MCED FDA Molecular & Clinical Genetics Panel votes in favor (10–0 / 6–4 / 7–2–1); Anthropic Claude discovers ART enzyme system in phage DNA; cytotoxic CD4+ T cells / CCL5–CCR5 age-associated myelopoiesis and maraviroc (Nature Aging); TranslAGE epigenetic clock responsiveness (Nature Medicine); HBG1/HBG2 base editing for SCD (NEJM).
GRAIL Galleri MCED FDA Molecular & Clinical Genetics Panel meeting today; CRISPR-Cas12a cryptic PCCA pseudoexon (propionic acidemia); Artemis (DCLRE1C) base editing for ART-SCID; USP22–SPI1–NAMPT BMSC senescence axis; 49 tissue-specific transcriptomic aging clocks.
FDA approves AQNEURSA (levacetylleucine) for ataxia in A-T; Inluriyo + Verzenio for ESR1-mutated ER+/HER2− breast cancer; WINREVAIR HYPERION PAH label update; BEAM-302 AATD base editing (ERS 2026); Galleri MCED AdComm set for 2026-09-23.
RamanOmics + ML barcode IDs senescent “zombie” cells (Nature Aging); laru-zova / VISTA XLRP pivotal LLVA; salvianolic acid senolytics in aged mice; Zanvastro (zilganersen) Alexander disease ASO approval; in-brain CRISPRi aging screens.
Dense RNA-modified Sem⁺ epegRNAs (Nature BME); AI-designed rentosertib proteomic aging clocks in IPF Phase 2a; MSK generative-AI de novo CAR binders; SNIPR001 CRISPR phage Phase 2 enrollment; intismeran (V940) + pembro Phase III RFS.
Insilico LongevityBench + Longevity Claw (Cell cover); PANXEON AI liquid biopsy early PDAC; IICM+ multimodal AI vs Oncotype DX in TAILORx; VERVE-102 PCSK9 base editing Phase 1 Heart-2.
FDA Ultragenyx Fayuvi for MPS IIIA; Nature prime assembly large integrations; adenine base editing HMSN-P models; Stanford virtual biotech AI agents; Anthropic Bay Area wet lab.
Novo Nordisk×Anthropic Claude R&D partnership; Insilico Longevity Vaccines AI initiative; late-life semaglutide mouse lifespan; AI phenotypic AMR vs S. pneumoniae; GenBio AIDO Cell.
Nature Medicine sex-specific organ aging clocks; FIX Padua AAV in adolescents (BBM-H901); PTCHD4 senescence/AKT; parental DNMs & ART mediation; clinical-scale WAS CRISPR-Cas9-AAV6.
Nature Aging frontal-cortex microprotein atlas / MKKS–microglia; ISEMBYLD (apitegromab) SMA approval; rentosertib AI drug Phase 3 IPF; CR composite aging biomarkers; Joenja APDS ages 4–11.
GPN-Star genomic LM; plasma proteomic aging clocks + 261 loci; lonvo-z HAE in vivo CRISPR priority review; CTX310 ANGPTL3; tBE CS-101/CS-206 β-hemoglobinopathies.
AlphaGenome Atlas; AlphaGenome Nature; rentosertib IPF + aging clocks; Casgevy ages 2+; npj Aging longevity genetics.
AlphaGenome Atlas lead; Nature AlphaGenome; FDA radiology AI landscape; Heartvue.Proton; Cercare segmentation.